Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Physicians Interrupting Patients

Physicians Interrupting Patients Letters Fourth, by making pain control a patients’ rights issue, The claims and the advice of experts in the field were erroneous. Joint Commission emphasized symptomatic treatment of pain Even the US Food and Drug Administration accepted Pur- over clinical investigation of the causes. due’s claims, approving labeling saying that iatrogenic addic- The Joint Commission did not follow the principles of evi- tion was “very rare” and that the delayed absorption of Oxy- dence-based medicine in enacting its pain management guide- Contin reduced the abuse liability of the drug. The US Food lines and did little to prevent or decrease opioid use once the and Drug Administration removed these unsubstantiated epidemic became apparent. claims from OxyContin’s labeling in 2001. However, the con- cept that iatrogenic addiction was rare and that long-acting Neeraj Chhabra, MD opioids were less addictive had been widely repeated, and Jerrold B. Leikin, MD studies refuting these claims were not published until sev- eral years later. After this experience, The Joint Commission Author Affiliations: Toxikon Consortium, John H. Stroger Jr. Hospital, Chicago, established much stricter processes to review any corporate Illinois (Chhabra); NorthShore University HealthSystem, Glenview, Illinois sponsorship of educational programs and to ensure that our http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Physicians Interrupting Patients

JAMA , Volume 318 (1) – Jul 4, 2017

Loading next page...
 
/lp/american-medical-association/physicians-interrupting-patients-nzKn4IZoDV
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.6489
pmid
28672308
Publisher site
See Article on Publisher Site

Abstract

Letters Fourth, by making pain control a patients’ rights issue, The claims and the advice of experts in the field were erroneous. Joint Commission emphasized symptomatic treatment of pain Even the US Food and Drug Administration accepted Pur- over clinical investigation of the causes. due’s claims, approving labeling saying that iatrogenic addic- The Joint Commission did not follow the principles of evi- tion was “very rare” and that the delayed absorption of Oxy- dence-based medicine in enacting its pain management guide- Contin reduced the abuse liability of the drug. The US Food lines and did little to prevent or decrease opioid use once the and Drug Administration removed these unsubstantiated epidemic became apparent. claims from OxyContin’s labeling in 2001. However, the con- cept that iatrogenic addiction was rare and that long-acting Neeraj Chhabra, MD opioids were less addictive had been widely repeated, and Jerrold B. Leikin, MD studies refuting these claims were not published until sev- eral years later. After this experience, The Joint Commission Author Affiliations: Toxikon Consortium, John H. Stroger Jr. Hospital, Chicago, established much stricter processes to review any corporate Illinois (Chhabra); NorthShore University HealthSystem, Glenview, Illinois sponsorship of educational programs and to ensure that our

Journal

JAMAAmerican Medical Association

Published: Jul 4, 2017

References